注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
VistaGen Therapeutics Inc是一家临床阶段的生物制药公司。该公司致力于为患有涉及中枢神经系统(CNS)的疾病和障碍的患者开发和商业化候选产品。其产品线包括PH94B,一种有潜力治疗多种焦虑症的神经活性鼻喷雾剂,正准备进行社交焦虑症(SAD)的III期临床试验,自杀意念、神经性疼痛、左旋多巴诱发的运动障碍(LID)和癫痫。其AV-101是7-氯-氰尿酸(7-Cl-KYNA)的口服前药,它是N-甲基-D-天冬氨酸受体(NMDAR)的甘氨酸共激动剂位点的有效和选择性完全拮抗剂,抑制NMDAR的功能,NMDAR是大脑中的一种离子型谷氨酸受体。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Shawn K. Singh | 58 | 2000 | CEO & Director |
Gordon Keller | - | 2022 | Chairman of Scientific Advisory Board |
Sanjay Johan Mathew | - | 2016 | Member of Clinical & Regulatory Advisory Board |
Jerry B. Gin | 80 | 2016 | Independent Director |
Thomas P. Laughren | - | 2016 | Member of Clinical & Regulatory Advisory Board |
Mark A. Smith | 68 | 2016 | Member of the Advisory Board |
Michael B. Liebowitz | - | 2018 | Member of CNS Clinical and Regulatory Advisory Board |
Joanne Curley | 54 | 2021 | Independent Director |
Mary L. Rotunno | 63 | 2021 | Independent Director |
Margaret M. FitzPatrick | 57 | 2021 | Independent Chair of the Board |
Gerard Sanacora | - | 2015 | Member of Clinical & Regulatory Advisory Board |
Maurizio Fava | - | 2015 | Member of Clinical & Regulatory Advisory Board |
Mark Steven Wallace | - | 2017 | Member of Clinical & Regulatory Advisory Board |
Ann Michelle Cunningham | 55 | 2019 | Director |
Jon S. Saxe | 88 | 2000 | Independent Lead Director and Life Science Advisor |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核